Orrick, Herrington & Sutcliffe LLP has notable expertise at the intersection of life sciences and tech. The firm’s vast work comprises capital raising, M&A, IP counseling and litigation, licensing agreements, and product liability litigation. It is led by Los Angeles-based David Gindler, focusing on IP litigation and licensing, alongside co-heads Thora Johnson in Washington DC, concentrating on data privacy and health tech regulations, and Stephen Thau, a transactional matters specialist in New York. The team welcomed new partners, including New York patent litigator Irena Royzman, joining from Herbert Smith Freehills Kramer, and Boston’s David Sharrow from Gunderson Dettmer LLP, experienced in commercial transactions. The FDA and regulatory team grew with the addition of Georgia Ravitz, joining the DC team from Wilson Sonsini Goodrich & Rosati, Amy Joseph, and Jeremy Sherer; the latter two joined the Boston team from Hooper, Lundy & Bookman, PC.
Legal 500 redaktioneller Kommentar

Kernmandanten

  • Immunogenx
  • Banneker Partners
  • Pacific Psychotherapy Technologies, Inc. (d/b/a Two Chairs)
  • Neuspera Medical
  • Syllable Corporation
  • Genentech, Inc
  • Corteva Agriscience, Inc
  • PDL Biopharma, Inc
  • Gilead Sciences, Inc
  • Virios Therapeutics

Highlight-Mandate

  • Advised ImmunogenX, Inc., a California based biotherapeutics company that caters to celiac disease research, in its acquisition by First Wave Biopharma, Inc.
  • Representing Genentech in a patent infringement lawsuit against Sandoz and Lek Pharmaceuticals, alleging infringement of a patent claiming novel granulate formulations of the drug pirfenidone, which Genentech sells under the name Esbriet®.
  • Advised Two Chairs, a California based company that operates a mental health therapy platform intended to offer in-person psychotherapy at clinics, in its US$72million Series C financing.

Anwält*innen

Praxisleitung

Thora Johnson; Stephen Thau; David Gindler

Weitere Kernanwält*innen

Irena Royzman; David Sharrow; Georgia Ravitz; Amy Joseph; Jeremy Sherer